N/A N=49 Randomized Double-blind Treatment

Cognitive Dysfunction in Parkinson's Disease

Parkinson's Disease

Bottom Line

View on ClinicalTrials.gov: NCT02346708 ↗

Enrolled (actual)

Serious AEs

2.2%

Results posted

Dec 2020

Primary outcome: Primary: Change in Magnetoencephalography (MEG) Connectivity Measures

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Real TMS (Device); Sham TMS (Device)
Age: Adult, Older Adult · 40+ yrs
Sex: All
Sponsor: University of Colorado, Denver
Primary completion: Dec 2018

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Magnetoencephalography (MEG) Connectivity Measures	—	—
SECONDARY Post-TMS Change From Baseline in Cognitive Scores	-1.4; 0; 0.3; 1; -9.1; -2.9	0.1

Summary

This study plans to learn more about the brain function related to thinking problems in individuals with Parkinson's disease.

Eligibility Criteria

Inclusion Criteria

Diagnosis of probable PD (using United Kingdom Brain Bank criteria)
Diagnosis of mild cognitive impairment
No unstable medical condition

Exclusion Criteria

Features suggestive of other causes of Parkinsonism or other neurological disorders
Prior deep brain stimulation (DBS) or ablation surgery
Evidence for active depression or Hospital Anxiety and Depression Scale (HADS) score greater than or equal to 11
Motor symptoms expected to interfere with scanning (e.g. sever tremor)
Contraindications to TMS, MEG, or MRI such as pregnancy, pacemaker, unstable cardiac disease, skull lesion, claustrophobia, history of epilepsy, or on medications known to lower seizure threshold
Implanted electronic devices or metal

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02346708). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.